Pacira BioSciences (PCRX) Projected to Post Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Pacira BioSciences to post earnings of $0.66 per share and revenue of $182.8560 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million for the quarter, compared to analysts’ expectations of $183.11 million. During the same quarter in the previous year, the firm earned $0.96 earnings per share. The business’s revenue was up 1.7% compared to the same quarter last year. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Up 3.8%

PCRX opened at $22.19 on Tuesday. The business’s 50-day simple moving average is $24.61 and its 200-day simple moving average is $24.54. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. Pacira BioSciences has a one year low of $16.00 and a one year high of $27.64. The stock has a market capitalization of $997.06 million, a P/E ratio of -7.98 and a beta of 0.40.

Insider Buying and Selling

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of the business’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total value of $116,267.04. Following the transaction, the director owned 11,393 shares in the company, valued at $269,672.31. The trade was a 30.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently added to or reduced their stakes in PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Pacira BioSciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock worth $677,000 after buying an additional 1,165 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Pacira BioSciences by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock worth $27,454,000 after buying an additional 367,869 shares in the last quarter. Strs Ohio acquired a new position in Pacira BioSciences in the 1st quarter worth $75,000. Marshall Wace LLP acquired a new position in Pacira BioSciences in the 2nd quarter worth $4,550,000. Finally, Sei Investments Co. lifted its holdings in Pacira BioSciences by 35.3% in the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock worth $606,000 after buying an additional 6,609 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PCRX. Truist Financial upgraded Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research report on Friday, July 25th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Pacira BioSciences in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $33.40.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.